ArticlePloS one2025
Comparative effectiveness and safety of insulin reference biologics versus biosimilars for types 1 and 2 diabetes mellitus: Protocol for a systematic review of real-world studies.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiabetes mellitus is characterized by insulin deficiency or resistance. The two main types of diabetes mellitus are type 1 (T1DM) and type 2 (T2DM). Insulin is the mainstay of therapy for T1DM and often the last-line therapy for T2DM. Biosimilar insulins are cost-saving alternatives to reference products that may improve access for patients and sustainability for healthcare systems. Despite supporting evidence from randomized controlled trials, biosimilar insulin uptake is poor, and real-world evidence of their safety and effectiveness is limited.
objectiveOur objective is to compare the real-world effectiveness and safety of insulin biosimilars versus reference products in adults with diabetes mellitus. ELIGIBILITY CRITERIA: We will include observational studies and open-label pragmatic randomized controlled trials. We will exclude other randomized controlled trials, literature reviews, meta-analyses, case series, case reports, study protocols, opinion pieces, and conference abstracts. Our primary effectiveness outcome will be glycated hemoglobin (HbA1c) and our primary safety outcome will be hypoglycemia. Our secondary outcomes will include fasting plasma glucose; time in range; microvascular complications; health-related quality of life; physician visits, emergency department visits, and hospital admissions for hypoglycemia, hyperglycemia, and diabetic ketoacidosis; weight gain; immunogenicity; injection site reactions; and incident cancers.
methodsThe search strategy combines three key concepts: diabetes, insulin, and biosimilars. We will conduct a structured search in MEDLINE, EMBASE, and International Pharmaceutical Abstracts. We will also search in grey literature databases, targeted websites, and the Google search engine. Finally, we will scan forward and backward citations. Articles will be screened, extracted, and appraised independently by two reviewers. Data will be descriptively summarized. DISCUSSION: Our systematic review of the real-world evidence on biosimilar insulins can help support clinical and policy decisions that impact the care of patients with T1DM or T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.